Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Common Equity (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Common Equity for 16 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 144.65% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 144.65% year-over-year, with the annual reading at $4.0 million for FY2025, 144.65% up from the prior year.
  • Common Equity for Q4 2025 was $4.0 million at Plus Therapeutics, down from $5.1 million in the prior quarter.
  • The five-year high for Common Equity was $14.8 million in Q3 2021, with the low at -$23.6 million in Q1 2025.
  • Average Common Equity over 5 years is $2.5 million, with a median of $3.0 million recorded in 2025.
  • The sharpest move saw Common Equity surged 11091.76% in 2021, then plummeted 563.87% in 2024.
  • Over 5 years, Common Equity stood at $14.8 million in 2021, then crashed by 56.32% to $6.4 million in 2022, then plummeted by 120.92% to -$1.3 million in 2023, then tumbled by 563.87% to -$8.9 million in 2024, then soared by 144.65% to $4.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $4.0 million, $5.1 million, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.